# A Phase I Study of IBI325 in Patients With Advanced Solid Tumor

> **NCT05246995** · PHASE1 · UNKNOWN · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 60 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** IBI325+Sintilimab

## Key facts

- **NCT ID:** NCT05246995
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-23
- **Primary completion:** 2023-03-23
- **Final completion:** 2023-11-23
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05246995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05246995, "A Phase I Study of IBI325 in Patients With Advanced Solid Tumor". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05246995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*